Titre : Benzyl viologène

Benzyl viologène : Questions médicales fréquentes

Termes MeSH sélectionnés :

Placenta
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Benzyl viologène : Questions médicales les plus fréquentes", "headline": "Benzyl viologène : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Benzyl viologène : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-07-17", "dateModified": "2025-04-13", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Benzyl viologène" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Viologènes", "url": "https://questionsmedicales.fr/mesh/D014755", "about": { "@type": "MedicalCondition", "name": "Viologènes", "code": { "@type": "MedicalCode", "code": "D014755", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D03.383.725.762.925" } } }, "about": { "@type": "MedicalCondition", "name": "Benzyl viologène", "alternateName": "Benzyl Viologen", "code": { "@type": "MedicalCode", "code": "D001594", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Takamasa Sagara", "url": "https://questionsmedicales.fr/author/Takamasa%20Sagara", "affiliation": { "@type": "Organization", "name": "Division of Chemistry and Materials Science, Graduate School of Engineering, Nagasaki University, Bunkyo 1-14, Nagasaki, 852-8521, Japan." } }, { "@type": "Person", "name": "Hironobu Tahara", "url": "https://questionsmedicales.fr/author/Hironobu%20Tahara", "affiliation": { "@type": "Organization", "name": "Division of Chemistry and Materials Science, Graduate School of Engineering, Nagasaki University, Bunkyo 1-14, Nagasaki, 852-8521, Japan." } }, { "@type": "Person", "name": "Jun Ying", "url": "https://questionsmedicales.fr/author/Jun%20Ying", "affiliation": { "@type": "Organization", "name": "College of Chemistry and Materials Engineering, Bohai University, Jinzhou, 121013, P. R. China." } }, { "@type": "Person", "name": "Aixiang Tian", "url": "https://questionsmedicales.fr/author/Aixiang%20Tian", "affiliation": { "@type": "Organization", "name": "College of Chemistry and Materials Engineering, Bohai University, Jinzhou, 121013, P. R. China." } }, { "@type": "Person", "name": "Xin Li", "url": "https://questionsmedicales.fr/author/Xin%20Li", "affiliation": { "@type": "Organization", "name": "Beijing Key Laboratory of Clothing Materials R&D and Assessment, Beijing Engineering Research Center of Textile Nanofiber, School of Materials design & Engineering, Beijing Institute of Fashion Technology, Beijing 100029, China." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Interactions between ultrasonographic cervical length and placenta accreta spectrum on severe postpartum hemorrhage in women with placenta previa.", "datePublished": "2023-01-09", "url": "https://questionsmedicales.fr/article/36572390", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/ijgo.14641" } }, { "@type": "ScholarlyArticle", "name": "Risk of preterm birth for placenta previa or low-lying placenta and possible preventive interventions: A systematic review and meta-analysis.", "datePublished": "2022-09-02", "url": "https://questionsmedicales.fr/article/36120450", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fendo.2022.921220" } }, { "@type": "ScholarlyArticle", "name": "Clinical Correlates of Placenta Accreta Spectrum Disorder Depending on the Presence or Absence of Placenta Previa: A Systematic Review and Meta-analysis.", "datePublished": "2022-09-07", "url": "https://questionsmedicales.fr/article/36075058", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1097/AOG.0000000000004923" } }, { "@type": "ScholarlyArticle", "name": "Serotonin system in the human placenta - the knowns and unknowns.", "datePublished": "2022-12-01", "url": "https://questionsmedicales.fr/article/36531448", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.3389/fendo.2022.1061317" } }, { "@type": "ScholarlyArticle", "name": "Research progress on N6-methyladenosine in the human placenta.", "datePublished": "2022-05-25", "url": "https://questionsmedicales.fr/article/35606944", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1515/jpm-2021-0665" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Composés hétérocycliques", "item": "https://questionsmedicales.fr/mesh/D006571" }, { "@type": "ListItem", "position": 3, "name": "Composés hétéromonocycliques", "item": "https://questionsmedicales.fr/mesh/D006573" }, { "@type": "ListItem", "position": 4, "name": "Pyridines", "item": "https://questionsmedicales.fr/mesh/D011725" }, { "@type": "ListItem", "position": 5, "name": "Composés de pyridinium", "item": "https://questionsmedicales.fr/mesh/D011726" }, { "@type": "ListItem", "position": 6, "name": "Viologènes", "item": "https://questionsmedicales.fr/mesh/D014755" }, { "@type": "ListItem", "position": 7, "name": "Benzyl viologène", "item": "https://questionsmedicales.fr/mesh/D001594" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Benzyl viologène - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Benzyl viologène", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-13", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Benzyl viologène", "description": "Comment diagnostiquer une intoxication au benzyl viologène ?\nQuels tests sont utilisés pour évaluer l'exposition ?\nQuels symptômes indiquent une intoxication ?\nY a-t-il des tests spécifiques pour le benzyl viologène ?\nComment évaluer la gravité de l'intoxication ?", "url": "https://questionsmedicales.fr/mesh/D001594?mesh_terms=Placenta&page=3#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Benzyl viologène", "description": "Quels sont les symptômes courants d'une exposition ?\nPeut-on avoir des effets neurologiques ?\nY a-t-il des symptômes à long terme ?\nComment se manifestent les irritations cutanées ?\nLes symptômes varient-ils selon la dose ?", "url": "https://questionsmedicales.fr/mesh/D001594?mesh_terms=Placenta&page=3#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Benzyl viologène", "description": "Comment prévenir l'exposition au benzyl viologène ?\nY a-t-il des formations spécifiques à suivre ?\nQuels sont les risques en milieu professionnel ?\nComment gérer les déversements en laboratoire ?\nQuelles sont les réglementations à suivre ?", "url": "https://questionsmedicales.fr/mesh/D001594?mesh_terms=Placenta&page=3#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Benzyl viologène", "description": "Quel est le traitement principal en cas d'intoxication ?\nDes antidotes existent-ils pour le benzyl viologène ?\nComment traiter les irritations cutanées ?\nQuand faut-il hospitaliser un patient ?\nQuels soins de soutien sont recommandés ?", "url": "https://questionsmedicales.fr/mesh/D001594?mesh_terms=Placenta&page=3#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Benzyl viologène", "description": "Quelles complications peuvent survenir après une intoxication ?\nLes complications sont-elles réversibles ?\nComment surveiller les complications ?\nY a-t-il des risques de cancer associés ?\nQuels sont les effets à long terme sur la santé ?", "url": "https://questionsmedicales.fr/mesh/D001594?mesh_terms=Placenta&page=3#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Benzyl viologène", "description": "Qui est le plus à risque d'intoxication ?\nL'âge influence-t-il le risque d'intoxication ?\nLes personnes avec des antécédents médicaux sont-elles à risque ?\nLes femmes enceintes sont-elles plus à risque ?\nComment l'environnement de travail affecte-t-il le risque ?", "url": "https://questionsmedicales.fr/mesh/D001594?mesh_terms=Placenta&page=3#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une intoxication au benzyl viologène ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Le diagnostic repose sur l'historique d'exposition et des tests de laboratoire pour détecter des métabolites." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour évaluer l'exposition ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Des analyses sanguines et urinaires peuvent être effectuées pour mesurer les niveaux de benzyl viologène." } }, { "@type": "Question", "name": "Quels symptômes indiquent une intoxication ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des troubles neurologiques, des nausées et des irritations cutanées." } }, { "@type": "Question", "name": "Y a-t-il des tests spécifiques pour le benzyl viologène ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas de tests spécifiques, mais des méthodes chromatographiques peuvent être utilisées." } }, { "@type": "Question", "name": "Comment évaluer la gravité de l'intoxication ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "La gravité est évaluée par l'intensité des symptômes et les résultats des tests de laboratoire." } }, { "@type": "Question", "name": "Quels sont les symptômes courants d'une exposition ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes incluent des vertiges, des maux de tête, des nausées et des irritations cutanées." } }, { "@type": "Question", "name": "Peut-on avoir des effets neurologiques ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des effets neurologiques comme des convulsions ou des troubles de la conscience peuvent survenir." } }, { "@type": "Question", "name": "Y a-t-il des symptômes à long terme ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Des effets à long terme peuvent inclure des troubles cognitifs ou des problèmes dermatologiques." } }, { "@type": "Question", "name": "Comment se manifestent les irritations cutanées ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les irritations cutanées peuvent se manifester par des rougeurs, des démangeaisons ou des éruptions." } }, { "@type": "Question", "name": "Les symptômes varient-ils selon la dose ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Oui, la gravité des symptômes dépend de la dose et de la durée d'exposition au benzyl viologène." } }, { "@type": "Question", "name": "Comment prévenir l'exposition au benzyl viologène ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "Utiliser des équipements de protection individuelle et suivre les protocoles de sécurité en laboratoire." } }, { "@type": "Question", "name": "Y a-t-il des formations spécifiques à suivre ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des formations sur la manipulation sécurisée des produits chimiques sont recommandées." } }, { "@type": "Question", "name": "Quels sont les risques en milieu professionnel ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Les risques incluent l'inhalation, le contact cutané et l'ingestion accidentelle de substances." } }, { "@type": "Question", "name": "Comment gérer les déversements en laboratoire ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Les déversements doivent être nettoyés immédiatement avec des procédures appropriées et des équipements de protection." } }, { "@type": "Question", "name": "Quelles sont les réglementations à suivre ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Il est essentiel de respecter les réglementations locales et internationales sur les produits chimiques." } }, { "@type": "Question", "name": "Quel est le traitement principal en cas d'intoxication ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Le traitement principal est l'élimination de l'exposition et le soutien symptomatique." } }, { "@type": "Question", "name": "Des antidotes existent-ils pour le benzyl viologène ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "Il n'existe pas d'antidote spécifique, le traitement est symptomatique et de soutien." } }, { "@type": "Question", "name": "Comment traiter les irritations cutanées ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Les irritations cutanées peuvent être traitées avec des crèmes apaisantes et des antihistaminiques." } }, { "@type": "Question", "name": "Quand faut-il hospitaliser un patient ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "L'hospitalisation est nécessaire en cas de symptômes graves ou de complications respiratoires." } }, { "@type": "Question", "name": "Quels soins de soutien sont recommandés ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Les soins de soutien incluent l'hydratation, le contrôle de la douleur et la surveillance des signes vitaux." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir après une intoxication ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications peuvent inclure des lésions organiques, des troubles neurologiques et des infections." } }, { "@type": "Question", "name": "Les complications sont-elles réversibles ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être réversibles, mais d'autres peuvent entraîner des séquelles permanentes." } }, { "@type": "Question", "name": "Comment surveiller les complications ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "La surveillance clinique et des tests de laboratoire réguliers sont nécessaires pour détecter les complications." } }, { "@type": "Question", "name": "Y a-t-il des risques de cancer associés ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Des études sont nécessaires, mais des expositions prolongées à des agents chimiques peuvent augmenter le risque de cancer." } }, { "@type": "Question", "name": "Quels sont les effets à long terme sur la santé ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Les effets à long terme peuvent inclure des troubles respiratoires et des problèmes neurologiques persistants." } }, { "@type": "Question", "name": "Qui est le plus à risque d'intoxication ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les travailleurs en laboratoire et ceux manipulant des produits chimiques sont les plus à risque." } }, { "@type": "Question", "name": "L'âge influence-t-il le risque d'intoxication ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les jeunes enfants et les personnes âgées peuvent être plus vulnérables aux effets toxiques." } }, { "@type": "Question", "name": "Les personnes avec des antécédents médicaux sont-elles à risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les personnes ayant des antécédents de maladies respiratoires ou neurologiques sont à risque accru." } }, { "@type": "Question", "name": "Les femmes enceintes sont-elles plus à risque ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les femmes enceintes peuvent être plus sensibles aux effets toxiques du benzyl viologène." } }, { "@type": "Question", "name": "Comment l'environnement de travail affecte-t-il le risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Un environnement de travail mal ventilé ou sans protection adéquate augmente le risque d'exposition." } } ] } ] }

Sources (2964 au total)

Interactions between ultrasonographic cervical length and placenta accreta spectrum on severe postpartum hemorrhage in women with placenta previa.

To explore the interactions between cervical length (CL) and placenta accreta spectrum (PAS) on severe postpartum hemorrhage (SPPH) in patients with placenta previa.... A retrospective case-control study was conducted at four medical centers in China, and 588 patients with placenta previa were included. The logistic regression analysis and restricted cubic splines (R... After adjusting for potential confounders, the negative linear dose-response relationship was confirmed by RCS, and the change of odds ratio (OR) was more significant when CL was 2.5 cm or less. The r... If CL was routinely performed during PAS evaluation, the increased OR of short CL and PAS could allow better patient preparation through counseling....

Risk of preterm birth for placenta previa or low-lying placenta and possible preventive interventions: A systematic review and meta-analysis.

To investigate the risk of preterm birth in women with a placenta previa or a low-lying placenta for different cut-offs of gestational age and to evaluate preventive interventions.... MEDLINE, EMBASE, CENTRAL, Web of Science, WHO-ICTRP and clinicaltrials.gov were searched until December 2021. Randomized controlled trials, cohort studies and case-control studies assessing preterm bi... In total, 34 studies were included, 24 reporting on preterm birth and 9 on preventive interventions. The pooled proportions were 46% (95% CI [39 - 53%]), 17% (95% CI [11 - 25%]), 10% (95% CI [7 - 13%]... Both women with a placenta previa and a low-lying placenta have an increased risk of preterm birth. This increased risk is consistent across all severities of preterm birth between 28-37 weeks of gest... PROSPERO https://www.crd.york.ac.uk/prospero/, identifier CRD42019123675....

Clinical Correlates of Placenta Accreta Spectrum Disorder Depending on the Presence or Absence of Placenta Previa: A Systematic Review and Meta-analysis.

To evaluate whether there are differences in risk factors and maternal outcomes of pregnancies complicated by placenta accreta spectrum depending on the presence or absence of placenta previa.... We performed a systematic search in Medline, EMBASE, ClinicalTrials.gov , and Web of Science from inception through April 25, 2022, without language or date restrictions. Search strategy included the ... Of the 1,122 articles screened, seven studies were included in the final review. Studies were included if they compared the risk factors and maternal outcomes of pregnancies complicated by placenta ac... A random-effects model was used to pool the mean differences or odds ratios (OR) and the corresponding 95% CIs using RevMan software. A total of 3,342 pregnancies complicated by placenta accreta spect... Pregnancies complicated by placenta accreta spectrum without previa had a more prominent association with IVF and prior D&C and myomectomy but were much less likely to be associated with prior cesarea... PROSPERO, CRD42022307637....

Research progress on N6-methyladenosine in the human placenta.

N6-methyladenosine (m6A) is one of the most common epigenetic modifications of eukaryotic RNA. Under the jointly reversible regulation of related enzymes, m6A regulates many aspects of RNA, such as tr... Data were compiled from 2018 to 2021 citations in PubMed and Google Scholar using the keywords: placenta AND N6-methyladenosine. Seven studies were included.... In this study, we introduced some conventional methods to detect m6A modification at the whole RNA, region (peak) and single base levels. We also summarized the current studies of m6A modification in ... Although the relevant reports are still in the preliminary stage and some results are inconsistent, studies on methylation m6A modification have contributed new ideas for the research of reproductive ...

Placenta Accreta Spectrum Disorders: A National Survey.

Describe the current practice of Canadian obstetricians-gynaecologists in managing placenta accreta spectrum (PAS) disorders from suspicion of diagnosis to delivery planning and explore the impact of ... We distributed a cross-sectional bilingual electronic survey to Canadian obstetricians-gynaecologists in March-April 2021. Demographic data and information on screening, diagnosis, and management were... We received 142 responses. Almost 60% of respondents said they had read the latest Society of Obstetricians and Gynaecologists of Canada clinical practice guideline on PAS disorders, published in July... This study demonstrates the impact of the Society of Obstetricians and Gynaecologists of Canada's PAS clinical practice guideline on management choices made by Canadian clinicians. Our study highlight...